SAVA News and Press, Cassava Sciences Inc. From 02/07/24

ADAS-Cog Scores Were Stable in a Group of Patients with Mild Alzheimer’s Who Received Drug Candidate Simufilam Continuously, Baseline to Month 24. Mild Alzheimer’s Patients Who Received Simufilam Non-Continuously Declined a Group Average of 1 Point on ADAS-Cog, Baseline to...

2024-02-06 21:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed against Cassava Sciences, Inc. (NASDAQ: SAVA) for securities law violations. Investors who purchased shares and have lost money are encouraged to contact the firm to learn more about how they might recover those l...

2024-02-03 10:15:00 ET Developing medicines for tricky-to-treat conditions like Alzheimer's disease is tough under the best of circumstances, and as investors in Cassava Sciences (NASDAQ: SAVA) know, sometimes the circumstances are far from ideal. The stock is now down by 23% over t...

2024-01-25 08:00:00 ET Summary Alex Carchidi calls the biotech sector highly risky and speculative, and says diversification is key for investors. Funding is currently difficult to obtain in the biotech industry, but a turnaround is expected. Competitive stories in gene editin...

2024-01-22 11:54:46 ET More on highly-shorted stocks Spirit Airlines: Don't Join The Panic Spirit Airlines: Ch.11 Bankruptcy Could Be A Better Option To Save The Airline Assessing JetBlue Airways During A Time Of Significant Uncertainty Over Spirit Airlines Turmoil ...

2024-01-18 01:02:00 ET Cassava Sciences (NASDAQ: SAVA) stock price has surged hard in the past few months, stinging short-sellers who benefited as it plunged for most of 2023. The shares have surged by more than 106% from the lowest point in November as hopes that its Alzhemer’s ...

2024-01-17 15:09:43 ET More on crowded shorts VinFast's Warm Reception In Contrast To Cold Shoulder Chinese EV Makers Are Getting ImmunityBio: Approval Likely Priced In, Yielding Mostly Risk For Would-Be Buyers Beyond Meat: No Path To Recovery VinFast Auto la...

2024-01-16 06:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-09 02:10:50 ET Summary Cassava's Market Position: Despite a $1 billion valuation, concerns about simufilam, its lone Alzheimer's drug, cast doubt on its prospects. Clinical Development Challenges: Simufilam faces rigorous Phase 3 trials, critical due to its unconvincing pr...